Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    "Gastro-enteropancreatic neuroendocrine tumor"
Show Display Options
Rank Status Study
1 Recruiting A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Condition: Gastroenteropancreatic Neuroendocrine Tumor
Intervention: Drug: Famitinib
2 Recruiting 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Condition: Gastro-entero-pancreatic Neuroendocrine Tumors
Interventions: Drug: Capecitabine;   Drug: Lu-PRRT;   Drug: SS-LAR
3 Terminated Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Gallium-68-DOTATATE PET/CT (index test);   Drug: Indium-111-Octreoscan (standard test)
4 Completed TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
Condition: Patients With Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68-Ga-DOTANOC
5 Active, not recruiting Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
Condition: Gastroenteropancreatic Neuroendocrine Tumours
Intervention:
6 Not yet recruiting [68 Ga]-DOTANOC PET/CT in GEP-NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: [68Ga]-DOTANOC PET/CT
7 Recruiting Community-based Neuroendocrine Tumor (NET) Research Study
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention:
8 Active, not recruiting Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Lanreotide Autogel 120 mg;   Drug: Temozolomide (TMZ)
9 Not yet recruiting Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in GEP NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 177Lu-OPS201
10 Completed 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: 68Ga-OPS202
11 Withdrawn Pasireotide Treatment for Neuroendocrine Tumor
Condition: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Drug: Pasireotide;   Drug: Diazoxide
12 Recruiting Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
13 Recruiting 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Intervention: Drug: Intravenous injection of 177Lu-octreotate
14 Completed Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Condition: Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions: Drug: Pasireotide LAR followed by Pasireotide LAR + Everolimus;   Drug: Everolimus followed by Pasireotide LAR + Everolimus
15 Recruiting Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: 177Lu-DOTATATE 25.9 GBq activity;   Drug: 177Lu-DOTATATE 18.5 GBq activity
16 Active, not recruiting Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Gastro Entero Pancreatic Neuroendocrine Tumors
Interventions: Drug: 28 GBq 177Lu-DOTATATE;   Drug: 22 GBq 177Lu-DOTATATE
17 Not yet recruiting Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Conditions: Gastroenteropancreatic Neuroendocrine Tumor;   Lung Neuroendocrine Neoplasm
Intervention: Procedure: NETest
18 Active, not recruiting The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Conditions: Gastro-enteropancreatic Neuroendocrine Tumor;   Secondary Malignant Neoplasm of Liver
Intervention: Other: magnetic resonance imaging (MRI)
19 Enrolling by invitation Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan
Condition: This Study Plans to Include 600 GEP-NET Patients.
Intervention:

Study has passed its completion date and status has not been verified in more than two years.